Oct 2026· Oncoimmunology· Vol 15· 0 citations· 71 references
Medicine
TL;DR
Collectively, irradiation does not abrogate DC function, and anti-tumor immunity in radio-immunotherapy does not strictly require cDC1s, and anti-tumor immunity in radio-immunotherapy does not strictly require cDC1s.
Abstract
Abstract Radiotherapy can enhance anti-tumor immunity by modulating the tumor microenvironment. However, its direct effects on dendritic cells (DCs) as key antigen-presenting cells remain poorly studied. Although DCs are considered relatively radioresistant, their functional capacity following irradiation is controversial and likely subset-dependent. In this study, we systematically analyzed the radiosensitivity and post-irradiation functional capacity of murine bone marrow-derived conventional type 1 DCs (cDC1s), which play a pivotal role in initiating CD8+ T cell-mediated anti-tumor immunity, conventional type 2 DCs (cDC2s), and monocyte-derived DCs (MoDCs) in vitro. After irradiation, DC viability and surface marker expression were assessed. To evaluate functional competence, DCs were stimulated with high hydrostatic pressure-inactivated tumor cells in combination with the adjuvants poly I:C and α-CD40 as a model system for therapeutic tumor vaccination, and the phagocytic activity, activation, and cytokine/chemokine secretion of the DCs were analyzed. DC radiosensitivity depended strongly on both the subset and maturation state, with mature DCs showing higher radioresistance than their immature counterparts, and with immature cDC1s being particularly more susceptible. Nevertheless, surviving DCs retained their ability to phagocytose tumor cells and, upon stimulation, upregulate activation- and migration-associated markers and secrete cytokines and chemokines. In vivo, radio-immunotherapy promoted DC migration to the tumor-draining lymph node and induced DC activation, as indicated by elevated concentrations of DC-related cytokines in the peripheral blood. Within a fixed radiotherapy plus checkpoint inhibition regimen, tumor growth delay was largely preserved in Batf3−/− mice, lacking the cDC1 subset. Collectively, irradiation does not abrogate DC function, and anti-tumor immunity in radio-immunotherapy does not strictly require cDC1s.
The biological rationale for DC-directed immunotherapy, tumor-induced DC dysfunction, next-generation DC platforms, in vivo DC targeting, DC-derived extracellular vesicles, negative and controversial clinical evidence, and rational combinations with checkpoint blockade and tumor-microenvironment-modulating strategies a...
Serena Zanotta, Domenico Galati· International Journal of Mol...· 0 citations
Effector B cell responses in solid malignancies are associated favorable response to immunotherapy. B cells can amplify anti-tumor immune responses via antibody production, antigen presentation, and pro-inflammatory cytokine release; yet B cells in cancer patients and tumor-bearing mice often fail to support these fu...
It is proposed that B cells support anti-tumor immunity when integrated into organized lymphoid niches and engaged in productive T cell-B cell cooperation, whereas they promote immune escape when redirected toward regulatory programs or suppressive myeloid interactions.
Yi-Nuo Wang, Xuan Che, Xiao-Qian Hu et al.· Critical reviews in oncology...· 0 citations
Dendritic cells (DCs) coordinate antigen presentation and immune-effector activation, but vaccine-induced immune responses have not consistently translated into clinical benefit. This focused narrative review evaluates therapeutic vaccination in established pancreatic cancer and potential adjuvant use after resection,...
Clear cell renal cell carcinoma (ccRCC) is an immunogenic cancer in which the use of Immune checkpoint inhibitors (ICIs) has provided clinical benefit. However, long-term therapeutic benefit is limited, as some do not respond initially while others develop resistance after treatment. Although extensive studies have bee...